FY2023 EPS Estimates for TG Therapeutics Inc (TGTX) Raised by Analyst

Share on StockTwits

TG Therapeutics Inc (NASDAQ:TGTX) – Jefferies Financial Group raised their FY2023 earnings per share estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, April 2nd. Jefferies Financial Group analyst C. Howerton now forecasts that the biopharmaceutical company will earn $0.40 per share for the year, up from their previous estimate of $0.30. Jefferies Financial Group has a “Buy” rating and a $8.00 price target on the stock.

A number of other analysts have also recently commented on TGTX. BidaskClub upgraded shares of TG Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. B. Riley initiated coverage on shares of TG Therapeutics in a report on Tuesday, January 8th. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright restated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, January 22nd. Zacks Investment Research cut shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 30th. Finally, ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 28th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. TG Therapeutics presently has a consensus rating of “Buy” and an average target price of $14.07.

Shares of TGTX stock opened at $8.32 on Thursday. TG Therapeutics has a 12 month low of $3.32 and a 12 month high of $16.00. The firm has a market cap of $727.52 million, a PE ratio of -4.36 and a beta of 2.31.

A number of institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC boosted its stake in TG Therapeutics by 4.3% in the 3rd quarter. Teachers Advisors LLC now owns 127,405 shares of the biopharmaceutical company’s stock worth $713,000 after purchasing an additional 5,221 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in TG Therapeutics by 10.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 71,312 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 6,812 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in TG Therapeutics by 3.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 286,843 shares of the biopharmaceutical company’s stock worth $1,606,000 after purchasing an additional 10,518 shares in the last quarter. Forbes J M & Co. LLP bought a new position in TG Therapeutics in the 4th quarter worth about $44,000. Finally, LPL Financial LLC bought a new position in TG Therapeutics in the 4th quarter worth about $49,000. Institutional investors own 55.59% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Read More: What is Net Asset Value (NAV)?

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Comparing Anaplan  & Its Rivals
Comparing Anaplan & Its Rivals
Head to Head Review: Twenty-First Century Fox  & TEGNA
Head to Head Review: Twenty-First Century Fox & TEGNA
Critical Comparison: Docusign  and Its Rivals
Critical Comparison: Docusign and Its Rivals
Principal Financial Group Inc. Cuts Position in Blackstone Mortgage Trust Inc
Principal Financial Group Inc. Cuts Position in Blackstone Mortgage Trust Inc
Insmed Incorporated  Shares Sold by Principal Financial Group Inc.
Insmed Incorporated Shares Sold by Principal Financial Group Inc.
Kelly Lawrence W & Associates Inc. CA Has $174,000 Position in United Technologies Co.
Kelly Lawrence W & Associates Inc. CA Has $174,000 Position in United Technologies Co.


© 2006-2019 Ticker Report